Pasireotide injection (Signifor)

Signifor (pasireotide) is covered only for adults (≥18) with Cushing’s disease when pituitary surgery is not an option or has not been curative; off‑label uses are not covered. Approvals are time‑limited (initial 4 months; continuation 1 year for responders; 4 months for those awaiting surgery or radiotherapy response) and require prescription by or consultation with an endocrinologist/Cushing specialist plus documentation of diagnosis, surgical candidacy or prior surgery outcome, response for continuation, and hepatic‑impairment dosing adjustments if applicable.

"Patient Currently Receiving Signifor/Signifor LAR - Approve for 1 year of continuation therapy if the patient has already been started on Signifor/Signifor LAR; patient has had a response, as deter..."

Sign up to see full coverage criteria, indications, and limitations.